Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial von Kappos, Ludwig, Fox, Robert J, Burcklen, Michel, Freedman, Mark S, Havrdová, Eva K, Hennessy, Brian, Hohlfeld, Reinhard, Lublin, Fred, Montalban, Xavier, Pozzilli, Carlo, Scherz, Tatiana, D'Ambrosio, Daniele, Linscheid, Philippe, Vaclavkova, Andrea, Pirozek-Lawniczek, Magdalena, Kracker, Hilke, Sprenger, Till

Volltext

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial von Comi, Giancarlo, Kappos, Ludwig, Selmaj, Krzysztof W, Bar-Or, Amit, Arnold, Douglas L, Steinman, Lawrence, Hartung, Hans-Peter, Montalban, Xavier, Kubala Havrdová, Eva, Cree, Bruce A C, Sheffield, James K, Minton, Neil, Raghupathi, Kartik, Ding, Ning, Cohen, Jeffrey A

Volltext

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial von Cohen, Jeffrey A, Comi, Giancarlo, Selmaj, Krzysztof W, Bar-Or, Amit, Arnold, Douglas L, Steinman, Lawrence, Hartung, Hans-Peter, Montalban, Xavier, Kubala Havrdová, Eva, Cree, Bruce A C, Sheffield, James K, Minton, Neil, Raghupathi, Kartik, Huang, Vivian, Kappos, Ludwig

Volltext

“No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis von Giovannoni, Gavin, Tomic, Davorka, Bright, Jeremy R, Havrdová, Eva

Volltext

Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study von Havrdová, Eva, Belova, Anna, Goloborodko, Alla, Tisserant, Anne, Wright, Andrew, Wallstroem, Erik, Garren, Hideki, Maguire, Ralph Paul, Johns, Donald R.

Volltext

Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement von Reyes, Saúl, Cunningham, Anthony L., Kalincik, Tomas, Havrdová, Eva Kubala, Isobe, Noriko, Pakpoor, Julia, Airas, Laura, Bunyan, Reem F., van der Walt, Anneke, Oh, Jiwon, Mathews, Joela, Mateen, Farrah J., Giovannoni, Gavin

Volltext

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial von Cree, Bruce AC, Selmaj, Krzysztof W, Steinman, Lawrence, Comi, Giancarlo, Bar-Or, Amit, Arnold, Douglas L, Hartung, Hans-Peter, Montalbán, Xavier, Havrdová, Eva K, Sheffield, James K, Minton, Neil, Cheng, Chun-Yen, Silva, Diego, Kappos, Ludwig, Cohen, Jeffrey A

Volltext

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study von Cohen, Jeffrey A, Comi, Giancarlo, Arnold, Douglas L, Bar-Or, Amit, Selmaj, Krzysztof W, Steinman, Lawrence, Havrdová, Eva K, Cree, Bruce AC, Montalbán, Xavier, Hartung, Hans-Peter, Huang, Vivian, Frohna, Paul, Skolnick, Brett E, Kappos, Ludwig

Volltext

Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis von Filippi, Massimo, Danesi, Romano, Derfuss, Tobias, Duddy, Martin, Gallo, Paolo, Gold, Ralf, Havrdová, Eva Kubala, Kornek, Barbara, Saccà, Francesco, Tintoré, Mar, Weber, Jörg, Trojano, Maria

Volltext

Thalamic atrophy is associated with development of clinically definite multiple sclerosis von Zivadinov, Robert, Havrdová, Eva, Bergsland, Niels, Tyblova, Michaela, Hagemeier, Jesper, Seidl, Zdenek, Dwyer, Michael G, Vaneckova, Manuela, Krasensky, Jan, Carl, Ellen, Kalincik, Tomas, Horáková, Dana

Volltext

Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: Yes von HAVRDOVA, Eva

Volltext

The potential of serum neurofilament as biomarker for multiple sclerosis von Bittner, Stefan, Oh, Jiwon, Havrdova, Eva Kubala, Tintore, Mar, Zipp, Frauke

Volltext

Altered Steroidome in Women with Multiple Sclerosis von Kancheva, Radmila, Hill, Martin, Velíková, Marta, Kancheva, Ludmila, Včelák, Josef, Ampapa, Radek, Židó, Michal, Štětkářová, Ivana, Libertínová, Jana, Vosátková, Michala, Kubala Havrdová, Eva

Volltext

Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis von Phelps, Richard, Winston, Jonathan A, Wynn, Daniel, Habek, Mario, Hartung, Hans-Peter, Havrdová, Eva Kubala, Markowitz, Glen S, Margolin, David H, Rodriguez, Claudio E, Baker, Darren P, Coles, Alasdair J

Volltext

The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges von Ghezzi, Angelo, Amato, Maria Pia, Edan, Gilles, Hartung, Hans-Peter, Havrdová, Eva Kubala, Kappos, Ludwig, Montalban, Xavier, Pozzilli, Carlo, Sorensen, Per Soelber, Trojano, Maria, Vermersch, Patrich, Comi, Giancarlo

Volltext

Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group von Rieckmann, Peter, Boyko, Alexey, Centonze, Diego, Elovaara, Irina, Giovannoni, Gavin, Havrdová, Eva, Hommes, Otto, Kesselring, Jurg, Kobelt, Gisela, Langdon, Dawn, LeLorier, Jacques, Morrow, Sarah A, Oreja-Guevara, Celia, Schippling, Sven, Thalheim, Christoph, Thompson, Heidi, Vermersch, Patrick

Volltext

Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients von Posová, Helena, Horáková, Dana, Čapek, Václav, Uher, Tomáš, Hrušková, Zdenka, Havrdová, Eva

Volltext

Real-Life Outcome in Multiple Sclerosis in the Czech Republic von Havrdova, Eva, Pavelcova, Miluse, Jönsson, Linus, Kobelt, Gisela

Volltext

Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease von Berger, Thomas, Adamczyk-Sowa, Monika, Csépány, Tünde, Fazekas, Franz, Fabjan, Tanja Hojs, Horáková, Dana, Ledinek, Alenka Horvat, Illes, Zsolt, Kobelt, Gisela, Jazbec, Saša Šega, Klímová, Eleonóra, Leutmezer, Fritz, Rejdak, Konrad, Rozsa, Csilla, Sellner, Johann, Selmaj, Krzysztof, Štouracˇ, Pavel, Szilasiová, Jarmila, Turcˇáni, Peter, Vachová, Marta, Vanecková, Manuela, Vécsei, László, Havrdová, Eva Kubala

Volltext

Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis von Garren, Hideki, Robinson, William H., Krasulová, Eva, Havrdová, Eva, Nadj, Congor, Selmaj, Krzysztof, Losy, Jacek, Nadj, Ilinka, Radue, Ernst-Wilhelm, Kidd, Brian A., Gianettoni, Jill, Tersini, Karen, Utz, Paul J., Valone, Frank, Steinman, Lawrence

Volltext